Clinical Trials Logo

Filter by:
NCT ID: NCT05861271 Recruiting - Clinical trials for Breast Cancer Stage I

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

For patients with HER2-positive early-stage breast cancer, NCCN guidelines recommend chemotherapy plus targeted therapy as the standard adjuvant treatment for patients with tumors larger than 1 cm or lymph node-positive. The APT study enrolled patients with stage I HER2-positive breast cancer and has confirmed the efficacy and safety of intravenous chemotherapy combined with targeted therapy, but only 2.2% of the patients enrolled in microinvasion are enrolled, and there is a lack of large sample size data to provide a treatment reference for these patients. In order to further explore the optimal strategy for adjuvant therapy in this type of patient, we designed a new clinical trial to evaluate the efficacy and safety of oral capecitabine plus pyrotinib as adjuvant therapy in previous retrospective studies.

NCT ID: NCT05861167 Recruiting - Crohn Disease Clinical Trials

SIIT Based on UST CDST in Patients With CD

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

ustekinumab (UST) can effectively induce and maintain clinical remission and mucosal healing of Crohn's disease (CD), but some patients still have poor response. Dose optimization is an effective way to improve the response rate of UST, and re-intravenous induction is a common way of optimization. For patients with secondary loss of response, about half of the patients can re-respond after dose optimization. We plan to use CDST-UST to stratify the response level of patients before treatment, select patients with poor response, and initially give multiple intravenous therapy as an intensive induction therapy strategy, so as to improve the response rate of these patients and achieve individualized treatment.

NCT ID: NCT05861128 Recruiting - Clinical trials for Ankylosing Spondylitis

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

NCT ID: NCT05861102 Recruiting - Clinical trials for Ankylosing Spondylitis

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Start date: July 20, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).

NCT ID: NCT05861063 Recruiting - Acne Atrophica Clinical Trials

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

Start date: February 11, 2023
Phase: Phase 4
Study type: Interventional

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

NCT ID: NCT05860868 Recruiting - Clinical trials for Locally Advanced Nasopharyngeal Carcinoma

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

Start date: May 2023
Phase: Phase 3
Study type: Interventional

This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

NCT ID: NCT05860790 Recruiting - Clinical trials for Venous Thromboembolism

Prospective Validation of Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery

Start date: March 10, 2023
Phase:
Study type: Observational

Validation of Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery: A Multicenter, Prospective, and Cohort Study

NCT ID: NCT05860595 Recruiting - Clinical trials for Transfusion-dependent Beta-Thalassemia

Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.

Start date: May 23, 2023
Phase: N/A
Study type: Interventional

This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with β-thalassemia major.

NCT ID: NCT05860465 Recruiting - Clinical trials for Locally Advanced or Metastatic Breast Cancer

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Start date: September 8, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

NCT ID: NCT05860400 Recruiting - Clinical trials for Coronary Artery Disease

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

Start date: May 17, 2023
Phase:
Study type: Observational [Patient Registry]

This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.